


Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca

May 24, 2016



How low can the potassium and sodium go with commonly prescribed blood pressure medications?

Clinical Question: What is the risk of electrolyte disturbances with diuretics and ACE Inhibitors and when should we check?

Bottom-line: Moderate hyponatremia ($\text{Na} < 130 \text{ mmol/L}$) and hypokalemia ($\text{K} < 3.2 \text{ mmol/L}$) each occur in ~4% of thiazide users, and hyperkalemia ($\text{K} > 5.4 \text{ mmol/L}$) occurs in 4% of ACE inhibitor (and angiotensin receptor blocker) users. Limited evidence suggests checking electrolytes in the first 2-4 weeks after starting, and again after increasing doses of these agents, and at least annually thereafter.

Evidence:

- Large hypertension Randomized Controlled Trials (RCTs) reporting sodium (Na) and Potassium (K).
 - ALLHAT sub-study¹ of 19,731 patients with normal baseline potassium: Results for chlorthalidone (12.5-25 mg) or lisinopril (10-40mg) or amlodipine (2.5-10 mg). At one year:
 - $\text{K} < 3.2 \text{ mmol/L}$: Chlorthalidone 3.5%, lisinopril 0.2%, amlodipine 0.3%.
 - $\text{K} > 5.4 \text{ mmol/L}$: Chlorthalidone 1.2%, lisinopril 3.6%, amlodipine 1.9%.
 - 8% of ALLHAT chlorthalidone users were on potassium supplements at five years.²
 - SHEP:³ 4,736 patients on chlorthalidone (12.5-25mg) or placebo. At any time in 4.5 years:
 - $\text{K} < 3.2 \text{ mmol/L}$: Chlorthalidone 3.9%, placebo 0.8%.
 - $\text{Na} < 130 \text{ mmol/L}$: Chlorthalidone 4.1%, placebo 1.3%.
 - Other large diuretic RCTs:
 - HYVET⁴ (indapamide vs placebo): Excluded patients with abnormal potassium.
 - Compared to placebo, K was 0.05 mmol/L lower with indapamide at two years.
 - Na not reported.
 - ANBP2⁵ (enalapril vs hydrochlorothiazide): Electrolyte results not reported.

- Chlorthalidone 12.5-25 mg decreases potassium on average by ~0.2-0.4 mmol/L⁶⁻⁸ about 0.1-0.2 mmol/L more than the same dose of hydrochlorothiazide.⁷
- Angiotensin receptor blockers (ARBs) have similar hyperkalemia rates as ACE inhibitors.⁹

Context:

- Diuretics are first line agents for uncomplicated hypertensive patients¹⁰ with additional advantage of low cost.¹¹
- Limited evidence suggests that thiazide induced hypokalemia or hyponatremia may occur within the first days to weeks of therapy,^{12,13} but can also develop years later.¹⁴
- Hypokalemia and hyponatremia risk factors: Women>men,^{1,15} increasing age,^{15,16} and diuretic dose.^{15,16}
 - Most patients with mild hypokalemia are asymptomatic, but symptoms can include weakness, myalgias, and cardiac arrhythmias.¹⁷
 - Moderate-to-severe hyponatremia (Na <130) may produce lethargy, dizziness, nausea, and confusion.¹⁸
- Combining diuretics with ACE¹⁹ or using potassium-sparing diuretics (like amiloride)²⁰ may help maintain normokalemia.

Authors:

Michael R. Kolber BSc MD CCFP MSc, Ricky D. Turgeon BscPharm ACPR PharmD

Disclosure:

Authors do not have any conflicts to disclose.

References:

1. Alderman MH, Piller LB, Ford CE, *et al.* Hypertension. 2012; 59:926-33.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA. 2002; 288:2981-97.
3. SHEP Cooperative Research Group. JAMA. 1991; 265:3255-64.
4. Beckett NS, Peters R, Fletcher AE, *et al.* N Engl J Med. 2008; 358:1887-98.
5. Wing LMH, Reid CM, Ryan P, *et al.* N Engl J Med. 2003; 348:583-92.
6. Savage PJ, Pressel SL, Curb D, *et al.* Arch Intern Med. 1998; 158:741-51.
7. Ernst ME, Carter BL, Zheng S, *et al.* Am J Hypertens. 2010; 23:440-6.
8. Dorsch MP, Gillespie BW, Erickson SR, *et al.* Hypertension. 2011; 57:689-94.
9. The ONTARGET Investigators. N Engl J Med. 2008; 358:1547-59.
10. Daskalopoulou SS, Rabi DM, Zarnke KB, *et al.* Can J Cardiol. 2015; 31:549-68.
11. Kolber MR, Nickonchuk T, Lee J, *et al.* Price Comparison of Commonly Prescribed Pharmaceuticals in Alberta 2016. Available at: <https://www.acfp.ca/wp-content/uploads/2016/03/ACFPPricingDoc2016.pdf>. Last accessed March 9, 2016.
12. Maronde RF, Milgrom M, Vlachaki ND, *et al.* JAMA. 1983; 249:237-41.
13. Barber J, McKeever TM, McDowell SE, *et al.* Br J Clin Pharmacol. 2015; 79(4):566-77.
14. Leung AA, Wright A, Pazo V, *et al.* Am J Med. 2011; 124:1064-72.
15. Sharabi Y, Illan R, Kamari Y, *et al.* J Hum Hypertens. 2002; 16:631-5.
16. Clayton JA, Rodgers S, Blakey J, *et al.* Br J Clin Pharmacol. 2006; 61:87-95.
17. Gennari FJ. N Engl J Med. 1998; 339(7):451-8.
18. Hwang KS, Kim G-H. Electrolyte Blood Press. 2010; 8:51-7.
19. Weber MA, Bakris GL, Jamerson K, *et al.* J Am Coll Cardiol. 2010; 56:77-85.
20. Brown MJ, Williams B, Morant SV, *et al.* Lancet Diabetes Endocrinol. 2016; 4:136-47.

Tools for Practice is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practicing family

physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity.

The ACFP has supported the publishing and distribution of the Tools for Practice library since 2009. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at <http://bit.ly/signupfortfp>. Archived articles are available at no extra cost on the [ACFP website](#).

You can now earn credits on Tools for Practice! In August 2014, the ACFP launched [GoMainpro, an online accreditation tool](#) to help facilitate MAINPRO® accreditation for the ACFP's Tools for Practice library which has been accredited for Mainpro-M1 credits by the College of Family Physicians of Canada (CFPC). The combination of the CFPC's Direct Entry Program and GoMainpro's tracking and reporting features provide an easy and convenient way to earn Mainpro-M1 credits.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.